Exhaled Nitric Oxide in Patients with Interstitial Lung Disease: A Pilot Study by Choi, JiYeon
3333333 
 Exhaled Nitric Oxide in Patients with Interstitial Lung Disease: A Pilot Study 
 
 
 
 
 
 
 
by 
JiYeon Choi 
BSN, Yonsei University, 1996 
MN, University of Washington, 2000 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
School of Nursing in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
 
 
2008 
 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF NURSING 
 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
 
JiYeon Choi 
 
 
It was defended on 
April 18, 2008 
and approved by 
 
Kevin F. Gibson, MD, Associate Professor, School of Medicine 
Richard Henker, PhD, RN, CRNA, Associate Professor, School of Nursing 
Jigme M. Sethi, MD, Assistant Professor, School of Medicine 
Thomas Zullo, PhD, Professor Emeritus, School of Nursing 
 
Dissertation Advisor: Leslie Hoffman, PhD, RN, FAAN, Professor, School of Nursing
 ii 
Copyright © by JiYeon Choi 
2008 
 iii 
Exhaled Nitric Oxide in Patients with Interstitial Lung Disease: A Pilot Study 
  
JiYeon Choi, PhD, RN 
University of Pittsburgh, 2008
Idiopathic pulmonary fibrosis (IPF) and sarcoidosis have an unknown etiology and require, 
periodic monitoring due to the insidious, unpredictable, and irreversible nature of disease 
progression. Exhaled nitric oxide (NO) has been used as a non-invasive marker of monitoring 
airway inflammation in patients with asthma and may have utility in monitoring airway 
inflammation in patients with IPF and sarcoidosis.  
The purpose of this pilot study was to explore the utility of exhaled NO in monitoring 
disease progression and response to therapy in patients with IPF and sarcoidosis. Individuals 
with IPF (n=15) and sarcoidosis (n=43), and healthy non-smokers (n=20) underwent single 
breath end-tidal NO (FeNO) measurement at 7 flow-rates (50, 100, 150, 200, 250, 300, & 400 
ml/s) using a chemiluminescence analyzer (LR1800; Logan Research, UK) following ATS/ERS 
guidelines (2005). Alveolar NO concentration (CAlvNO) and airway NO flux (JAWNO) were 
estimated using the model by Tsoukias, et al. (1998). In individuals with active sarcoidosis, 
follow-up measurements were performed after being on treatment 
The findings in patients with IPF were: 1) FeNO was not significantly different from that 
of controls for the 7 flow rates; 2) while there was no significant difference in JAWNO compared 
with controls, CAlvNO was significantly higher, and 3) CAlvNO showed significant negative 
correlations with FEV1% and FVC%.  In patients with sarcoidosis,: 1) FeNO at a flow rate of 50 
ml/sec was lower than that of controls with marginal statistical significance (p=.05); 2) JAWNO , 
was significantly lower in patients with sarcoidosis compared to controls; there was no 
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significant difference in CAlvNO; 3) CAlvNO showed significant negative correlations with 
FVC% and DLCO%. The subset of patients with active sarcoidosis (n=8) had significantly lower 
CAlvNO compared with those with inactive sarcoidosis (n=35), but no significant difference in 
FeNO and JAWNO. In six patients with active sarcoidosis who completed follow-up at various 
intervals, exhaled NO (FeNO, CAlvNO and JAWNO) did not change significantly as a result of 
treatment. Due to a large inter-subject variability in FeNO, confounding from medications used 
to manage this disease and variable concentrations of ambient NO, exhaled NO does not appear 
to be effective in detecting changes in airway inflammation in this population.  
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1.0  INTRODUCTION 
Interstitial lung disease (ILD) encompasses a broad range of heterogeneous disease groups, 
which share common pathologic characteristics, including scarring of the lung and progressive 
deterioration of alveolar gas exchange capacity (Lindell & Jacobs, 2003; G Raghu, 1998; 
Strieter, 2001). Idiopathic pulmonary fibrosis (IPF) and sarcoidosis are two examples of 
commonly occurring ILD (King, 2007). Although relatively rare, IPF and sarcoidosis cause 
substantial patient burden due to the insidious, unpredictable, and irreversible changes in lung 
function associated with these conditions (G Raghu, 1998).  Although medications can decrease 
symptoms, there is no therapy that reverses lung damage.  Lung transplantation is the only 
known option for cure (Lindell & Jacobs, 2003). For these reasons, timely monitoring and 
symptom management are important in order to slow disease progression and improve quality of 
life (Lindell & Jacobs, 2003).  
  An important component of the management of IPF and sarcoidosis involves periodic 
monitoring of symptoms and pulmonary function tests (American Thoracic Society, 1999b; 
Demedts & Costabel, 2002). These methods are non-invasive, but often not specific enough to 
identify changes consistent with disease progression. Therefore, it would be beneficial to identify 
a non-invasive technique that is easy to use and provides timely information on disease 
progression and response to treatment.         
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 Exhaled nitric oxide (NO) was first discovered in the exhaled breath of rabbits, guinea 
pigs, and humans by Gustaffson et al. in 1991 (Gustaffson, Leone, & Persson, 1991). This 
discovery was followed by intense interest in the potential use of exhaled NO as a noninvasive 
marker of inflammation and oxidative stress in the lung (S. Kharitonov & Barnes, 2001). The 
technique used to monitor exhaled NO is easy to perform, non-invasive, inexpensive, and 
requires minimal cooperation from patients (Choi, Hoffman, Rodway, & Sethi, 2006). Testing 
can be performed in multiple settings, age, and disease groups (S. Kharitonov & Barnes, 2001).  
In early studies, exhaled NO was measured using a single breath technique wherein 
patients exhaled at a constant flow rate over a defined time interval (American Thoracic Society, 
2005).  Recently, a multiple flow-rate technique has been advocated as a more promising 
method.  When multiple flow rate measurements are used, it is possible to estimate NO levels 
from two lung compartments, i.e., the conducting airways and alveoli (American Thoracic 
Society, 2005; Tsoukias & George, 1998). The multiple flow-rate measurement technique is 
considered more appropriate for ILD patients because disease typically involves both airway 
compartments (Strieter, 2001).  
The use of exhaled NO in detecting and monitoring airway inflammation has been 
extensively studied in patients with asthma, cystic fibrosis, and lung transplant (S. Kharitonov & 
Barnes, 2000). However, few studies were identified that tested the utility of exhaled NO as a 
monitoring method in patients with ILD with either the single-breath (Moodley, Chetty, & 
Lalloo, 1999; O'Donnell et al., 1997; Paredi et al., 1999; Riley et al., 1997; Wilsher, Fergusson, 
Milne, & Wells, 2005; D.H. Yates, Kharitonov, & Barnes, 1997; Ziora, Kaluska, & Kozielski, 
2004) or multiple flow-rate technique (Brindicci, Goh, Wells, & Barnes, 2005; Girgis, Gugnani, 
Abrams, & Mayes, 2002; Lehtimaki et al., 2001).  
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According to findings from studies using the single-breath measurement in patients with 
ILD, exhaled NO levels are positively correlated with inflammatory cell count in 
bronchioalveolar lavage (BAL) during active inflammation (Paredi et al., 1999). However, once 
fibrotic changes develop exhaled NO levels may not be different (Wilsher et al., 2005) or lower 
than healthy controls (Paredi et al., 1999), with no correlation with clinical data (Wilsher et al., 
2005). Each study had several limitations (see Table 1-3). Data were collected cross-sectionally 
(O'Donnell et al., 1997; Paredi et al., 2003; Riley et al., 1997; Wilsher et al., 2005; Ziora et al., 
2004). The sample size was small and a heterogeneous group of ILD patients was recruited 
rather than those with one type of ILD (Paredi et al., 1999; Riley et al., 1997). Because the single 
breath measurement technique was used, findings did not provide information about differences 
in the conducting airways (flux of airway NO, JAWNO [nl/sec]) or alveoli (alveolar NO 
concentration, CAlvNO [ppb]).  
Several more recent studies used the multiple flow-rate technique in patients with ILD 
(Brindicci et al., 2005; Girgis et al., 2002; Lehtimaki et al., 2001). Again, there were differences 
in patient diagnoses that might impact study findings, e.g., IPF and hypersensitive pneumonitis 
(Lehtimaki et al., 2001), scleroderma with and without pulmonary hypertension (Girgis et al., 
2002). Nevertheless in all studies alveolar NO was higher in ILD patients than controls 
(Brindicci et al., 2005; Girgis et al., 2002; Lehtimaki et al., 2001) especially when the disease 
involved active inflammation in the lungs, such as usual interstitial pneumonia (Brindicci et al., 
2005). In addition, there was a significant negative relationship between alveolar NO and clinical 
data, such as diffusing capacity for carbon monoxide (DLCO), and vital capacity (VC) (Girgis et 
al., 2002; Lehtimaki et al., 2001). As in studies using a single breath measurement, there were 
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limitations including a small sample size, mixed diagnoses, and insufficient data regarding 
correlations with clinical variables. 
1.1 PURPOSE 
The purpose of this pilot study was to determine if exhaled NO (FeNO, CAlvNO, JAWNO) could 
be used to identify changes in disease progression and response to therapy in patients with 
idiopathic pulmonary fibrosis (IPF) and sarcoidosis diagnosed using current international 
guideline (American Thoracic Society, 1999b; Demedts & Costabel, 2002). Healthy non-
smokers were recruited as a control group (Control). Results were also examined to determine if 
a correlation existed between exhaled NO levels and other clinical variables (dyspnea and 
pulmonary function tests) and disease activity.  
1.2 SPECIFIC AIMS 
The specific aims were: 
1) To compare FeNO levels measured at 7 flow rates (50, 100, 150, 200, 250, 300, and 400 
ml/s) between patients with IPF or sarcoidosis and healthy non-smoking subjects (controls); 
2) To compare calculated airway wall NO flux (JAWNO) and alveolar NO concentrations 
(CAlvNO) between patients with IPF or sarcoidosis and healthy non-smoking subjects 
(controls); 
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3) To examine the relationship between exhaled NO (FeNO, CAlvNO, JAWNO) and selected 
clinical variables (dyspnea, pulmonary function tests) in patients with IPF or sarcoidosis.  
The exploratory aims were:  
1) To compare exhaled NO (FeNO, CAlvNO, JAWNO) between patients with active sarcoidosis 
and patients with inactive sarcoidosis;  
2) To examine changes in exhaled NO (FeNO, CAlvNO, JAWNO) over time (from initial clinic 
visit to follow-up visit) in patients with active sarcoidosis completed follow-up.  
1.3 DEFINITION OF TERMS 
1) IPF (Idiopathic Pulmonary Fibrosis): a distinctive type of chronic fibrosing interstitial 
pneumonia of unknown cause limited to the lungs confirmed by histologic diagnosis 
(Demedts & Costabel, 2002). 
2) Sarcoidosis: a systemic granulomatous disease that primarily affects the lungs and lymphatic 
systems diagnosed by histological evidence of noncaseating epithelioid cell granulomas due 
to an unknown cause or not the result of local sarcoid reactions (American Thoracic Society, 
1999b). 
3) Active sarcoidosis (active pulmonary sarcoidosis): Active pulmonary sarcoidosis is 
diagnosed as present when the patient meets 3 or more of following criteria over 6-12 weeks: 
a) complaints of progressive respiratory symptoms, such as shortness of breath, cough, 
dyspnea on exertion; b) exercise desaturation tests that indicate deterioration of 10% or 
greater in arterial oxygen saturation  by pulse oximetry (SpO2) or an increase in flow 
requirement of supplemental oxygen during exertion; c) pulmonary function test results 
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(FVC, DLCO) that indicate a deterioration of 10% or greater, or d) evidence of worsening 
radiographical change (American Thoracic Society, 1999b). 
4) FeNO (ppb): Fraction of NO in exhaled breath measured at various flow rates (50, 100,  150, 
200, 250, 300, and 400 ml/sec). 
5) CAlvNO (ppb): Steady state NO concentration in alveolar air estimated by the multiple flow 
rate model of Tsoukias (George, Hogman, Permutt, & Silkoff, 2004; Tsoukias & George, 
1998).  
6) JAWNO (nl/sec): Airway wall NO flux. The quantity of NO transferred from bronchial wall to 
luminal air per unit time estimated by the multiple flow rate model of Tsoukias (George et 
al., 2004; Tsoukias & George, 1998). 
1.4 CONCEPTUAL FRAMEWORK 
The conceptual framework shown in Figure 1 illustrates the proposed relationships among 
variables examined in this study. As conceptualized, exhaled NO levels (FeNO, CAlvNO, 
JAWNO) will be influenced by the presence of IPF and sarcoidosis. There may be correlations 
between NO levels (FeNO, CAlvNO, JAWNO) and selected clinical variables: 1) dyspnea; 2) 
pulmonary function tests (FEV1%, FVC%, and DLCO%); and/or 3) disease activity. 
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 Figure 1. Conceptual Framework 
Note: SOBQ, Shortness of Breath Questionnaire 
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2.0  BACKGROUND AND SIGNIFICANCE  
2.1 INTERSTITIAL LUNG DISEASE (ILD) 
Interstitial lung disease (ILD), a diffuse parenchymal lung disease, consists of a heterogeneous 
group of diseases that share common characteristics, including scarring of lung tissue and 
progressive loss of the normal gas exchange capacity of the alveolar capillary membrane (G 
Raghu, 1998). In many cases, ILD affects both alveolar and airway tissue (Strieter, 2001). By 
etiology, there are three groups of ILD. The first group includes conditions that result from 
occupational or environmental exposure, mainly organic or inorganic dusts, e.g., asbestosis, 
silicosis, hypersensitivity pneumonitis also known as farmers’ lung. Second, ILD can develop as 
a consequence of systemic connective tissue diseases, such as systemic lupus erythematosus, 
rheumatoid arthritis, or scleroderma. The third group includes the many types of ILD with an 
unknown etiology (King, 2007). IPF and sarcoidosis are included in this category.  
2.1.1 Idiopathic Pulmonary Fibrosis (IPF) 
 Idiopathic Pulmonary Fibrosis (IPF) is also known as cryptogenic fibrosing alveolitis (Dempsey, 
Kerr, Gomersall, Remmen, & Currie, 2006) or in histopathologic diagnosis, as “usual interstitial 
pneumonia (UIP)” (Demedts & Costabel, 2002).  IPF is characterized by interstitial 
inflammation with fibrosis, which results in chronic irreversible scarring with honeycombing 
 8 
changes mainly in the lung parenchyma (Dempsey et al., 2006). In the US, approximately 15,000 
new cases are diagnosed every year (Coultas & Hughes, 1996). The estimated incidence rate is 
20 to 30 per 100,000 and the condition occurs more commonly in men than in women (Coultas 
& Hughes, 1996). Typically, at the time of presentation, patients are between 40 and 70 years 
(American Thoracic Society, 2000). About two-thirds of IPF patients are older than 60 years 
(American Thoracic Society, 2000). Although ethnic variation has not been clearly established, 
IPF related mortality is known to be higher in white Caucasians than other ethnic groups 
(American Thoracic Society, 2000). Various risk factors have been suggested including cigarette 
smoking, use of antidepressants, chronic aspiration secondary to gastroesophageal reflux disease, 
occupational or environmental exposure, viral infection, and genetic predisposition (Lindell & 
Jacobs, 2003).  
 The exact causative mechanism of IPF remains under investigation.  It is believed that 
an aberration of wound healing mechanisms in the lung results in subsequent irreversible fibrotic 
changes in scattered areas of lung parenchyma (Dempsey, 2006). The consequent chronic 
inflammation and scarring cause a progressive decline in the gas exchanging capacity of alveolar 
capillary membrane (Demedts & Costabel, 2002). Patients typically present with complaints of 
non-specific respiratory symptoms, such as cough, shortness of breath, decrease in exercise 
tolerance, fatigue, etc. (Lindell & Jacobs, 2003).  The diagnosis is established by suggestive 
findings, including evidence of  restrictive lung disease, a decrease in the DLCO, and changes in 
high resolution computed tomography (HRCT) (Lindell & Jacobs, 2003). The differential 
diagnosis of IPF is a challenge because it is necessary to rule out conditions which cause similar 
symptoms. In order to confirm the diagnosis, lung biopsy is required (American Thoracic 
Society, 2000). Due to heterogeneous pathological changes in IPF, it is recommended that 
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biopsies be taken from multiple lobes (Dempsey et al., 2006). Nevertheless, due to frailty, 
advanced age, or co-morbidities, surgical biopsy may not be recommended due to the risk of 
complications (Dempsey et al., 2006). 
               Management of IPF is directed toward minimizing symptoms and improving quality of 
life. Conventional pharmacologic management such as corticosteroids, other immunosuppressive 
drugs (e.g. azathoprine, cycpophosphamide), and antifibrotic agents (e.g. colchicines) are used 
either individually or in combination (Lindell & Jacobs, 2003). A number of additional agents 
are under investigation but, to date, there is no curative therapy. Although survival varies 
depending on age at diagnosis and the number of risk factors, median survival after initial 
diagnosis is less often than three years (Bjoraker et al., 1998). Lung transplantation is the only 
treatment that has the potential to improve survival (Alalawi, Whelan, Bajwa, & Hodges, 2005; 
Lindell & Jacobs, 2003).  
2.1.2 Sarcoidosis 
In the US, the annual incidence of sarcoidosis ranges from approximately 5 to 40 out of 100,000, 
depending on ethnicity and gender. According to the only population-based study by Rybicki et 
al. (1997), African Americans tend to have a higher incidence rate (35.5 per 100,000) than white 
Caucasians (10.9 per 100,000) (Rybicki, Major, Popovich, Maliarik, & Iannuzzi, 1997).  Females 
also have a slightly higher incidence rate (6.3 per 100,000) than males (5.9 per 100,000) 
(Rybicki et al., 1997).  Sarcoidosis can occur across the lifespan, but most patients are diagnosed 
between the ages of 25 to 40 years (American Thoracic Society, 1999b).   
 Sarcoidosis is characterized by the presence of noncaseating granulomas in various 
organs resulting from uncontrolled cell-mediated immune reactions (Nunes, Soler, & Valeyre, 
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2005). The disease can affect multiple organs but predominantly involves the skin, eyes, lymph 
nodes, and chest (Nunes et al., 2005). Both genetic susceptibility and environmental factors are 
believed to be involved. Genetic susceptibility affects the presentation, progression and 
prognosis (American Thoracic Society, 1999b; Nunes et al., 2005). A variety of environmental 
factors including infectious agents (mycobacteria, parasites, and fungi), inorganic agents 
(beryllium, zirconium, and zluminum), and organic particles are suspected as potential triggers 
(American Thoracic Society, 1999b; Nunes et al., 2005).  
            The clinical presentation and progression of pulmonary sarcoidosis is highly variable 
(Costabel, 2001). In more than 50% of cases, diagnosis is made incidentally by radiographic 
abnormalities while patients are asymptomatic (Costabel, 2001). The diagnosis requires 
histologic confirmation of the presence of noncaseating granulomas and exclusion of other 
conditions that produce similar symptoms  (American Thoracic Society, 1999b). The goal at the 
time of diagnosis include: 1) histologic confirmation of the disease; 2) determining the extent 
and severity of organ involvement; 3) determining if the disease is inactive or active, and 4) 
determining the potential benefit of initiating therapy (American Thoracic Society, 1999b). 
Pulmonary involvement occurs in more than 90% of sarcoidosis patients (American Thoracic 
Society, 1999b). In advanced stages of pulmonary sarcoidosis, fibrotic changes involve the entire 
lung parenchyma and may also involve the larynx, trachea and bronchi. Patients experience a 
progressive loss of functional ability and eventually die from acute respiratory failure (Nunes et 
al., 2005). 
             Similar to IPF, management for patients with sarcoidosis focuses on symptom 
management and pharmacologic treatment (Nunes et al., 2005). Corticosteroids are the first line 
of treatment (Nunes et al., 2005). As a second line, immunosuppressive agents, e.g.,  
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hydroxychloroquine, methotrexate or azathioprine, are recommended (Nunes et al., 2005). The 
long-term benefits of those medications remain under investigation (Nunes et al., 2005). 
Spontaneous remission may occur with no treatment and the appropriate time of initiating 
treatment is therefore still controversial (Costabel, 2001).  
 In summary, the exact causative mechanisms of IPF and sarcoidosis are still under 
investigation. With the exception of lung transplantation, there are no effective current treatment 
options (American Thoracic Society, 1999b, 2000). The progress of both diseases is insidious, 
unpredictable and irreversible. In order to slow disease progression and improve quality of life, 
the timing of therapy is important. Hence, it would be beneficial to develop a non-invasive 
monitoring method that can be frequently and easily used to detect changes in lung function and 
monitor response to therapy.  
2.2 EXHALED NITRIC OXIDE (NO) 
2.2.1 Early History of NO 
Nitric oxide (NO) was first discovered by Joseph Priestly in 1772 (Chinard, 1995). NO was 
viewed as a “non-respirable ” poisonous gas for over 200 years, because the focus was on its 
adverse actions, such as a cause of smog, acid rain and cancer (Kreuzer & Patel, 1971; Norman 
& Keith, 1965; Terrell & Schmeltz, 1968; Weissbecker, Creamer, & Carpenter, 1971). In 1980, 
Furchgott and Zawadzki reported that the vascular endothelium contained an endothelium 
derived relaxing factor (EDRF) (Furchgott & Zawadzki, 1980; Vallance & Chan, 2001) and later 
it was suggested that EDRF may be NO (Furchgott, 1996; RM Palmer, Ferrige, & Moncada 
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1987). In 1987, Palmer et al. (RM Palmer et al., 1987) and Ignarro et al. (Ignarro, Buga, & 
Wood, 1987) reported that the actions and characteristics of NO in arteries and veins were 
identical to those of EDRF. Following this report, scientists began to investigate the physiologic 
role of NO. In 1998, the Nobel Prize for Physiology or Medicine was awarded for these 
discoveries (The Nobel Foundation, 1998).  
2.2.2 NO Synthesis 
Endogenous NO is formed via the action of the enzyme, NO synthase (NOS) which converts L-
arginine into L-citrulline and NO (Bateman, Sharpe, & Ellis, 2003; Ignarro, Fukuto, Griscavage, 
& Rogers, 1993; Moncada  & Higgs, 1993; R Palmer, Ashton, & Moncada 1988). This reaction 
requires oxygen, and cofactors, such as nicotinamide adenine dinucleotide phosphate (NADPH), 
flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and  tetrahydrobiopterin 
(BH4)(Adding & Gustaffson, 2003; S. Kharitonov & Barnes, 2001; Ricciardolo, 2003).   
There are three isoforms of NOS, termed neural NOS (nNOS), endothelial NOS (eNOS), 
and induced NOS (iNOS).  The isoforms are the product of three different genes located on three 
different chromosomes (chromosome 7, 12, and 17, respectively) (Ricciardolo, 2003).  The two 
constitutive isoforms (nNOS and eNOS) require influx of calcium (Ca2+) and calmodulin for 
activation (Bredt & Snyder, 1990). The third isoform, iNOS, is ready for physiologic activity 
immediately after translation, because Ca2+ and calmodulin are already tightly bonded (Belvish, 
Mitchell, & Yacoub, 2003). Therefore, activation of iNOS is Ca2+ independent (Bateman et al., 
2003; Ignarro et al., 1993; Murad, 1996).  
nNOS is released from nerve cells (Belvish et al., 2003) and is known to be up-regulated 
by heat, electrical activation (Reiser, Kline, & Vaghy, 1997), light, ischemic injury (Prabhakar et 
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al., 1996; Zhang, Chopp, Gautam, Zaloga, & Schmidt, 1994), and sex hormones, including 
estradiol and testosterone (Luckman, Huckett, Bicknell, Voisin, & Herbison, 1997; Reily, 
Zamorano, Stopper, & Mills, 1997). Pro-inflammatory cytokines, such as tumor necrosis factor-
alpha (TNF-α), may reduce the expression of nNOS (Fosterman, Boissel, & Kleinert, 1998; 
Reiser et al., 1997).  eNOS is released by endothelial cells (Mitchell et al., 1991), which may be 
up-regulated by shear stress and proliferation of tissue (Corson et al., 1996; Xino, Zhang, & 
Dramond, 1997), and down-regulated by endotoxin or cytokines (Belvish et al., 2003). iNOS,  
the Ca2+- independent isoform, is normally not expressed or expressed only very low levels and 
induced after several hours of exposure by pro-inflammatory cytokines, such as TNF-α, 
interleukin-1β (IL-1β), and interferon-γ (IFN-γ ) (Belvish et al., 2003). In the respiratory system, 
when these proinflammatory cytokines or oxidants activate nuclear factor κB (NF-κ B), the most 
important transcription factor for regulating iNOS induction (Xie, Kashiwabara, & Nathan, 
1994), iNOS is expressed in various cells: bronchial epithelial cells (Guo et al., 1995; Kobzik et 
al., 1993; Watkins, Peroni, Basclain, Garlepp, & Thompson, 1997), alveolar macrophages 
(Kobzik et al., 1993; Tracey et al., 1994; Wang et al., 1998), nasal vascular epithelial cells and 
nasal ciliated epithelial cells (Furukawa et al., 1996). iNOS has a dual nature: it involves cell 
protection as well as cell damage (Bateman et al., 2003; Brune, Knethen, & Sandau, 2000; Wink 
& Mitchell, 1998). 
2.2.3 Physiologic Actions of NO 
Once formed, NO exists for a brief time (6-10 seconds) before being converted into other 
substances (Myron, 1995). NO is an essential biological molecule in the human body that is 
involved in various functions: selective vasodilator, bronchodilator, neurotransmitter, and 
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inflammatory mediator (Adding & Gustaffson, 2003; Barnes & Belvish, 1993; Culotta & 
Koshland, 1992; Vallance & Chan, 2001).  
In the respiratory system, physiologic actions of NO have three different aspects. NO 
produces regulative, protective, and deleterious effects (Bateman et al., 2003; Brune et al., 2000; 
Wink & Mitchell, 1998). In the airways, NO regulates tracheobronchial circulation and 
maintains baseline bronchial caliber (Barnes & Liu, 1995; Higenbottam, 1995; Kuo, Liu, & 
Barnes, 1992). NO suppresses airway plasma exudation (Bernareggi, Mitchell, Barnes, & 
Belvish, 1997; Erjefalt, Erjefalt, Sundler, & Persson, 1997) and stimulates mucociliary clearance 
(Jain, Rubinstein, Robbins, Leise, & Sisson, 1993; Ramnarine, Khawaja, Barnes, & Rogers, 
1996; Tamaoki, Chiyotani, Kondo, & Konno, 1995), a primary airway defense mechanism.  In 
the pulmonary circulation, NO acts as a tonic vasodilator (Stampler, Loh, Roddy, Currie, & 
Creager, 1994) by altering pulmonary vascular resistance (Albert et al., 1997; Cooper et al., 
1996) and ventilation-perfusion (V/Q) matching during hypoxic pulmonary vasoconstriction 
(Archer, Tolins, Raij, & Weir, 1989; Barnes & Liu, 1995; Persson, Gustaffson, Wiklund, 
Moncada , & Hedqvist, 1990; Sprague, Thiemermann, & Vane, 1992).  
Optimal NO production in the pulmonary system requires oxygen (Adding & Gustaffson, 
2003). In the well-oxygenated pulmonary blood vessel, active NO production maintains 
pulmonary vascular tone. In hypoxemic regions, the low oxygen concentration decreases NO 
production. Decreased NO production results in minimal stretch (vasodilation) of pulmonary 
vessels, which decreases blood flow to poorly oxygenated lung regions (Adding & Gustaffson, 
2003; Grimminger, Spriestersbach, Weissman, Walmrath, & Seeger, 1995; Nelin, Thomas, & 
Dawson, 1996). This action shunts blood to better oxygenated regions and, thereby, promotes 
more optimal V/Q matching. NO may also act as a ventilatory depressant by controlling 
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hyperventilation (Persson et al., 1990) via an inhibitory effect on respiratory neurons (Barros & 
Branco, 1998) and respiratory muscle force (El Dwairi et al., 1998). 
Involvement of NO is “multifaceted” as well as “paradoxical (Wink & Mitchell, 1998). ” 
As a regulator, NO controls bronchodilation, vascular tone and mucus secretion (Ricciardolo, 
2003). As a cytoprotective agent, NO defends the body against reactive oxygen species (ROS), 
such as hydrogen peroxide (H2O2), alkyl hydroperoxides, and superoxide (Wink & Mitchell, 
1998). NO is known to neutralize oxidants associated with oxidative stress and attenuate ROS 
mediated toxicity (Wink et al., 1994).  The up-regulation of iNOS activity increases NO 
production and creates a toxic environment for viruses, bacteria, fungi, parasites, e.g., herpes 
simplex virus, mycobacterium tuberculosis (Lowenstein, Dinerman, & Snyder, 1994). This 
activity of iNOS in airway epithelium explains the role of NO in airway host defense (Guo et al., 
1995; Shaul et al., 1994). 
Although NO itself is not inherently cytotoxic, depending on intracellular redox milieu, 
NO can react as a cytotoxic or cytoprotective agent. Reaction of NO with oxygen or redox metal 
complexes produces NO and NO-derived chemical species thereby creating its deleterious 
effects. The powerful oxidant, peroxynitrite (ONOO-), is formed by the reaction between NO and 
O2-, which inhibits enzyme function, causes damage in DNA, induces lipid peroxydation, and 
increases cellular susceptibility to radiation, toxic metals, and alkylating agents (Beckman & 
Koppenol, 1996; Wink & Mitchell, 1998). 
2.2.4 Measuring NO in Exhaled Breath 
Because of its short half-life and rapid oxidation in biological tissues, NO measurement was a 
challenge. Initially, researchers tried to indirectly measure NO using different assays, such as 
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cGMP, nitrites (NO2-), or citrulline, which reflect NO activity, NO metabolism, or NO synthesis, 
respectively (Adding & Gustaffson, 2003). In 1970, environmental scientists discovered that NO 
could be directly measured using the principle of chemiluminescence (Fontijin & Ronco, 1970). 
When NO reacts with ozone, it produces energy in the form of light that is proportional to the 
amount of NO and can be measured with a luminometer (Fontijin & Ronco, 1970).  The 
pioneering NO studies in 1987 by Palmer and colleagues used this chemiluminescence method 
(RM Palmer et al., 1987). However, because of the difficulty in avoiding oxidation of NO to 
NO2-, they summed the amount of NO and NO2- and separated the NO value through calculation. 
In 1991, Gustafsson et al. reasoned that NO may escape through exhalation, due to its gaseous 
nature and low solubility in fluid, an observation led their discovery of NO in exhaled breath 
(Gustaffson et al., 1991). Their work, the first to use the chemiluminescence method to measure 
NO in exhaled breath, led to an explosion of research focused on identifying the potential role of 
exhaled NO in diagnosis and monitoring of various respiratory diseases (S. Kharitonov & 
Barnes, 2001).  
Exhaled gas analysis is particularly attractive to the practice of nursing because of many 
advantages. It is non-invasive, easy to learn and perform (patients perform a slow, steady 
exhalation into a mouthpiece connected with the machine). Adults and children can easily follow 
the test and there is no learning effect or systematic error when serial measurements are 
performed (S. Kharitonov, 2004). The test can be reliably performed in those older than 7 years 
of age and the majority of children 4 to 7 years of age (S. Kharitonov, 2004). Test results are 
immediately displayed on the monitor screen and testing requires minimal space and technical 
support. Accordingly, serial exhaled NO analysis may be helpful in decreasing use of other 
invasive or expensive tests. Nurses can apply this non-invasive test in research and clinical 
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practice in populations across the lifespan. When the equipment becomes more compact and less 
expensive, this technique may be expanded to primary care clinics in the community and, 
perhaps, even home care settings. However, a search identified a limited nursing literature 
addressing NO (Cicutto & Downey, 2004). The proposed study will provide important 
information about exhaled NO in patients with IPF and sarcoidosis that may form the basis for 
testing future interventions.  
2.2.5 Factors Influencing Exhaled NO Levels   
Exhaled NO levels may be influenced by several factors. The influence of body mass index 
(BMI), gender, and age are not yet clear (Ekroos, Tuominen, & Sovijarvi, 2000; Tsang et al., 
2001). Cigarette smoking is known to significantly decrease exhaled NO levels, possibly because 
NO in cigarette down-regulates NOS production (S. A. Kharitonov, Robbins, Yates, Keatings, & 
Barnes, 1995). Alcohol consumption has been shown to decrease exhaled NO levels in patients 
with asthma, presumably because ethanol decreases iNOS production (D. H. Yates, Kharitonov, 
Robbins, Thomas, & Barnes, 1996). Whether similar changes occur in healthy individuals has 
not been determined. Caffeine consumption significantly decreases exhaled NO levels in healthy 
volunteers (Bruce, Yates, & Thomas, 2002), but does not produce significant changes in exhaled 
NO in patients with asthma (Taylor, Smith, Cowan, Herbison, & Taylor, 2004). Although the 
effect of diet on exhaled NO levels is not clear, there may be some influence from food 
supplements containing L-arginine, or nitrate (S. A. Kharitonov, Lubec, Lubec, Hjelm, & 
Barnes, 1995; Olin et al., 2001; Popovic, Zeh, & Ochoa, 2007). Therefore, it is recommended 
that patients refrain from eating, drinking caffeinated beverages, or smoking for one hour before 
measurements are made (American Thoracic Society, 1999a). Some studies indicate that ambient 
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NO alters measured values (Baraldi et al., 1998; Byrnes, Dinarevic, Busst, Shinebourne, & Bush, 
1997), whereas others do not (Baraldi et al., 1998; C. Borland, Cox, & Higenbottam, 1993; S. 
Kharitonov, Logan-Sinclair, Busset, & Shinebourne, 1994; Kimberly, Nejadnik, Giraud, & 
Holden, 1996; Massaro et al., 1996; Piacentini et al., 1998).  Therefore, it is important to 
measure ambient NO when performing this test. Inhaled corticosteroids (ICS) may also alter 
exhaled NO levels. Exhaled NO is decreased in response to the use of ICS (S. Kharitonov, 
Donnelly, Corradi, Montuschi, & Barnes, 2000; S. Kharitonov, Yates, & Barnes, 1996). For this 
reason, it is important to control for the effect of ICS analyzing results obtained from this 
measurement.   
2.2.6 Exhaled NO measurement   
Two techniques are currently used for measuring exhaled NO (American Thoracic Society, 
2005). In offline measurement, expired air is collected into a reservoir and the concentration of 
NO is analyzed from this sample (American Thoracic Society, 2005). The more commonly used 
method involves analyzing the concentration of end tidal exhaled NO (FeNO) (American 
Thoracic Society, 2005) (Figure 2).   
 Figure 2. End tidal exhaled NO measurement 
          
The concentration of FeNO is inversely related to flow-rate. Therefore, when patients 
exhale at lower flow rates, more NO is contributed from the airways relative to the overall 
concentration in the breath (Tsoukias & George, 1998). This characteristic flow pattern occurs 
because the slower flow rate allows more time for NO to enter from the airway and be exhaled. 
(Figure 3).  
 
Figure 3. Flow rate dependent characteristics of FeNO 
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 Using this flow-rate dependent characteristic, Tsoukias et al.(1998) developed a two-
compartment model that can be used to calculate steady NO levels in alveoli (CAlvNO, ppb) and 
flux of NO from the airway wall (JAWNO, nl/sec). According to this model, the lung comprises 
two separate regions: a rigid and non-expansible airway compartment and an expansible alveolar 
compartment (George et al., 2004; Tsoukias & George, 1998). Two parameters, CAlvNO, and 
JAWNO, define the contributions from each compartment. While alveolar NO (CAlvNO) moves 
through the conducting airways toward the mouth during exhalation, NO diffuses from airway 
wall (JAWNO). CAlvNO and JAWNO are estimated by measuring NO elimination rate (VLNO, 
nl/s), which is a product of FeNO and measurement flow-rate. Once FeNO is measured at two or 
more flow-rates (VE, ml/s), a linear relationship can be seen between VE and VLNO (Figure 4).  
 
Figure 4. Schematic of Tsoukias technique to estimate the flow-independent NO parameters using a 
minimum of 2 constant exhalation flow rates 
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CAlvNO and JAWNO can be estimated from the slope and intercept. This technique has the 
advantage of providing more specific information about inflammation as contributions of the two 
compartments can be analyzed separately (American Thoracic Society, 2005). Therefore, this 
two-compartment model is considered to be a promising research tool. 
2.3 EXHALED NO IN ILD 
The utility of exhaled NO in diagnosis and monitoring has been extensively studied in patients 
with asthma, cystic fibrosis, and lung transplant recipients (S. Kharitonov & Barnes, 2001) with 
utility most strongly established in patients with asthma (Choi et al., 2006). FeNO levels increase 
during periods of airway inflammation and FeNO monitoring is an FDA approved option for 
asthma management (US Food and Drug Administrations, 2003). 
Relatively few studies have examined the utility of exhaled NO in patients with IPF and 
sarcoidosis. In 10 human studies, 7 used the single-breath technique (Moodley et al., 1999; 
Moodley & Lalloo, 2001; O'Donnell et al., 1997; Paredi et al., 1999; Riley et al., 1997; Wilsher 
et al., 2005; Ziora et al., 2004) and 3 used multiple flow-rate measurement (Brindicci et al., 
2005; Girgis et al., 2002; Lehtimaki et al., 2001). All recruited a heterogeneous group of patients, 
e.g., scleroderma with ILD, scleroderma with pulmonary hypertension (Girgis et al., 2002), 
pulmonary fibrosis (Riley et al., 1997), IPF (Paredi et al., 1999), progressive systemic sclerosis 
with ILD and without ILD (Moodley & Lalloo, 2001), IPF and hypersensitive pneumonitis 
(Lehtimaki et al., 2001), and sarcoidosis (Moodley et al., 1999; O'Donnell et al., 1997; Wilsher 
et al., 2005; Ziora et al., 2004).   
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The following tables summarize findings from studies in patients with sarcoidosis which 
used the single breath technique for measurement of exhaled NO (Table 1), studies which used 
the same measurement technique in patients diagnosed with various types of ILD (Table 2) and 
studies which used the multiple flow rate technique (Table 3).        
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Table 1. Single breath FeNO measurement in sarcoidosis 
 
Note: All studies used single breath end-tidal exhaled NO measurement, 
¶ Significantly high FeNO levels compared with healthy controls (p<.05); *p < .05 
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 Table 2. Single breath FeNO measurement in other ILD 
 
Note: The study by Riley et al.(1997) used continuous monitoring of mixed expired NO during exercise 
intervention (NO production rate [VENO, nl/min] was calculated; FeNO was measured at rest and peak 
exercise. Other 2 studies used single breath end-tidal FeNO measurement.  
PPH=Primary Pulmonary Hypertension; PF=Pulmonary Fibrosis; PSS=Progressive Systemic Sclerosis 
¶ Significantly high FeNO levels compared with other groups in sample (p<.05); * p<.05 
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Table 3. Multiple flow-rate exhaled NO measurement in ILD 
 
Note: HP=Hypersensitive Pneumonitis; SSc= Systemic Sclerosis; PH=Pulmonary Hypertension; 
PPH=Primary Pulmonary Hypertension; ¶ Significantly high CAlvNO levels compared with healthy non-
smokers (p=0.008); ¶¶ Significantly high CAlvNO levels compared with sarcoidosis (p = 0.002); ¶¶¶ 
Significantly high CAlvNO levels compared with healthy non-smokers (p = 0.001); * p < 0.05; ** p < 
0.005 
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2.3.1 FeNO in IPF 
One study was identified that compared FeNO in patients with IPF (Paredi et al., 1999). Paredi et 
al. (1999) measured exhaled NO in patients with IPF (n=11) and healthy controls (n=13). In this 
study, 5 patients with IPF were on oral prednisone of 30 mg/day. FeNO was compared between 
patients with IPF and healthy controls. In patients with IPF, FeNO was compared depending on 
the use of oral prednisone. Potential correlations with clinical data, including BAL cell counts 
and pulmonary function tests, were also examined.  Significantly higher levels of exhaled NO 
were found in patients with IPF (11.2 ± 1.0 ppb) compared with healthy controls (6.9 ± 0.5 ppb). 
In patients with IPF, exhaled NO was lower in those treated with oral prednisone, compared to 
those not on treatment (9.0 ± 1.0 ppb, n=5, and 13.1 ± 1.0 ppb, n=6, respectively; p < 0.05).  
BAL cell counts, particularly lymphocyte counts, were significantly higher in treated compared 
to untreated patients (16.6 ± 1.8 % and 7.2 ± 1.7 %, respectively; p < 0.05).  
2.3.2 FeNO in sarcoidosis      
In studies enrolling patients with sarcoidosis, four studies used the single flow-rate end tidal NO 
measurement. One study by Moodley et al. (1999) compared FeNO levels before and after 
corticosteroid treatment, whereas the remaining three studies used a cross-sectional, correlational 
design (O'Donnell et al., 1997; Ziora et al., 2004; Wilsher et al., 2005). With the exception of 
Ziora et al. (2004), all used a chemiluminescence analyzer from the same manufacturer (model 
LR2000; Logan Research, Rochester, UK) and the same sampling flow-rates (Moodley et al., 
1999; O'Donnell et al., 1997; Wilsher et al., 2005).  The studies were designed to answer three 
questions: 1) Is there a significant increase or decrease in FeNO levels in patients with ILD 
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compared with control subjects; 2) Is FeNO significantly correlated with disease activity as 
determined by pulmonary function tests, histological findings, radiographic findings, etc., and 3) 
Is there a change in FeNO in response to treatment?   
Regarding the first question, contradictory findings were reported. Three of the four 
studies reported no significant difference when FeNO values were compared in patients with 
sarcoidosis and healthy controls, regardless of sarcoid disease activtiy. A summary of their 
findings follows. O’Donnell et al. (1997) measured FeNO in 10 patients with active sarcoidosis 
who were not on treatment and 12 healthy non-smoking controls (O'Donnell et al., 1997). The 
mean FeNO in patients with untreated active sarcoidosis was not significantly different from 
healthy controls (6.9 ±4.5 ppb vs. 6.6 ±4.0 ppb, p=.60). Wilsher et al. (2005) measured FeNO in 
59 sarcoidosis patients. Of these, 4 few subjects were stage 0 (n=3) or stage IV (n=1) and the 
remainder were stage I to stage III (n= 13, 21, and 14, respectively) (Wilsher et al., 2005). None 
were on oral or ICS for at least 3 months prior to measurement. The median FeNO in untreated 
sarcoidosis patients (n=59, 6.8 ppb, range 2.4 – 21.8) was not significantly different from healthy 
controls (n=44, 6.3 ppb, range 1.6-28). Ziora et al. (2004) measured FeNO in patients with 
sarcoidosis who had been diagnosed for < 2 years prior to enrollment. Among 27 patients, 21 
were diagnosed with active sarcoidosis. None were on oral or ICS prior to measurement. Patients 
with sarcoidosis had higher FeNO levels than controls, with marginal statistical significance (6.7 
± 0.5, 5.17 ± 0.73, respectively, p= 0.05). When FeNO was compared in patients with active 
sarcoidosis (n=21) with those with inactive sarcoidosis (n=6), there was no significant difference 
(p=.124). A comparison of patients with stage I, II and III disease showed no statistical 
significance (p=.985).  
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In contrast, Moodley et al. (1999) reported significantly higher FeNO levels in 12 
patients with newly diagnosed sarcoidosis compared to healthy controls. At enrollment, when 
none of the patients were prescribed oral or ICS or immunosuppressive agents, FeNO levels 
were significantly higher than healthy non-smokers (n=21; 9.8 ± 0.4, 4.1 ± 0.2, respectively, p 
<.001). After baseline measurement of FeNO, 8 patients were prescribed oral prednisone 
(40mg/day for 6 wks). FeNO was significantly decreased after treatment (from 9.7 ± 0.5 to 5.9 ± 
0.7 ppb, p=0.01). This is the only study examined changes in FeNO before and after steroid 
treatment in sarcoidosis and the only study to report higher FeNO levels in patients with 
sarcoidosis.  
When correlations were examined between FeNO and other clinical variables, except for 
DLCO in one study (Ziora et al., 2004), none of clinical variables examined demonstrated a 
significant correlation with FeNO, e.g., BAL NO2, BAL leukocyte count (O'Donnell et al., 1997), 
BAL CD4/CD8 ratio (Moodley et al., 1999), serum ACE (Moodley et al., 1999; O'Donnell et al., 
1997), total serum IgE (Wilsher et al., 2005), FEV1 (Moodley et al., 1999; Wilsher et al., 2005), 
FVC (Moodley et al., 1999; Wilsher et al., 2005).  For DLCO, both a moderate positive 
correlation (r= 0.515, p =0.03) (Ziora et al., 2004) and no significant correlation were reported 
(Wilsher et al., 2005).  As noted previously, heterogenous sample characteristics may explain 
these inconsistent results.  
2.3.3 CAlvNO and JAWNO in IPF and sarcoidosis 
One abstract was identified that compared CAlvNO and JAWNO in patients with IPF (n=12) and 
sarcoidosis (n=9), and healthy non-smokers (n=15) (Brindicci et al., 2005). Two patients with 
IPF were on immunosuppressive therapy; use of ICS was not reported. Whereas there was no 
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difference in JAWNO among three groups, CAlvNO was significantly higher in patients with IPF 
(4.0 ± 0.4 ppb) compared with patients with sarcoidosis or healthy non-smokers (2.8 ± 0.3 ppb, 
p=0.0002; 1.4 ± 0.1 ppb, p=0.001, respectively) (Brindicci et al., 2005). In this study, patients 
with sarcoidosis showed higher CAlvNO compared with healthy non-smokers, but its statistical 
significance was not described. 
2.3.4 Exhaled NO in other ILD 
The following studies examined diverse groups of patients with mixed types of ILD and reported 
varying findings. Riley et al. (1997) were the first to measure exhaled NO in patients with 
various ILD using offline measurement. In this study, 6 patients with ILD had various diagnoses, 
including sarcoidosis (n=3), scleroderma (n=2), cryptogenic fibrosing alveolitis (n=1). Three out 
of 6 patients with ILD were on oral prednisone (mean 6.7 mg/day, range 5-10 mg/day). In this 
study, FeNO was significantly lower in PF patients (5.9 ± 1.6 ppb) compared to those with PPH 
(13.6 ± 8.3 ppb) and healthy controls (13.6 ± 6.0 ppb). 
Moodley & Lalloo (2001) measured FeNO in patients with progressive systemic sclerosis 
(PSS) with and without interstitial lung disease (PSS-ILD, PSS-non ILD, respectively), and 
healthy controls. All patients with PSS-ILD were diagnosed with pulmonary hypertension 
whereas all patients with PSS-non ILD had no clinical evidence of pulmonary hypertension. 
After the initial diagnosis of PSS-ILD, the patients were placed on a regimen of azathioprine and 
prednisone for 6 months and FeNO was measured before and after treatment.  FeNO was 
significantly higher in the PPS-non ILD group (9.6 ± 0.7 ppb) compared to the PPS-ILD group 
(6.2 ± 0.6 ppb, p<.001) and controls (6.3 ± 0.2 ppb, p<.001). In PSS-ILD group, there was no 
significant change in FeNO after 6 months of azathioprine and prednisone (from 6.2 ± 0.6 ppb to 
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6.4 ± 0.3 ppb). Similar to findings from Riley et al. (1997) that reported no difference in FeNO 
between patients with PPH and healthy controls (13.6 ± 8.3 ppb, 13.6 ± 6.0 ppb, respectively), 
this study showed no significant difference in FeNO of patients with PSS-ILD, those who also 
diagnosed with pulmonary hypertension, and healthy controls (6.2 ± 0.6 ppb, 6.3 ± 0.2 ppb, 
respectively). Such results are contradictory to the findings from the study that reported 
significantly lower FeNO in patients with PSS with pulmonary hypertension compared to PSS 
without pulmonary hypertension and healthy controls (20 ± 6 ppb, 149 ± 19 ppb, 80 ± 7 ppb, 
respectively) (S. Kharitonov, Cailes, Black, DuBois, & Barnes, 1997). It appears likely that 
patients with PSS-ILD had ongoing inflammation evidenced by markedly high neutrophil, 
lymphocyte and eosinophil counts in BAL fluid, which were higher than counts recorded for 
PSS-non ILD patients. The presence of pulmonary hypertension among the patients with PSS-
ILD may be another factor causing a lower FeNO.  
Lehtimaki et al. (2001), measured FeNO at 3 flow-rates (100, 175 and 370 ml/s) in ILD 
(n=17), and healthy controls (n=57). Then, CAlvNO and JAWNO were calculated. In this study, 
ILD patients included those diagnosed with hypersensitive pneumonitis (n=7, 1 on oral 
prednisone) and IPF (n=10, 4 on prednisone and 1 on azathioprine). CAlvNO was significantly 
higher in ILD patients (4.1 ± 0.3 ppb) compared to healthy controls (1.1 ± 0.1 ppb, p<0.001), 
whereas JAWNO was not significantly different (0.7 ± 0.1 nl/s, 0.7 ± 0.1 nl/s, respectively, 
p<0.001). Because effect of treatment with oral prednisone or azathiprine was not controlled at 
baseline, it is difficult to interpret whether the changes in CAlvNO related to disease activity or 
medications. For those who were not on treatment at baseline (n=8), follow-up measurements 
were performed after 2 months of treatment (allergen avoidance, n=3; oral prednisone, n=4; and 
azathiprine, n=1). After treatment, there was a significant decrease in CAlvNO (from 4.0 ± 0.6 
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ppb to 2.4 ± 0.5 ppb, p=0.011) and significant improvement in DLCO (from 59 ± 6 % to 76 ± 3 
%, p=0.006), whereas no change was found in JAWNO (from 0.5 ± 0.1 nl/sec to 0.6 ± 0.1 nl/sec, 
p=NS). Because the focus of the study was on the effect of treatment in patients, it is difficult to 
determine separate changes resulting from the disease process. Regarding exhaled NO and 
clinical data, a significant negative correlation was reported between CAlvNO and DLCO (r=- .55, 
p=0.02) and vital capacity (r= -.54, p=0.03). Again, due to heterogenous diagnoses and treatment 
effects, it is difficult to explain the results. 
Girgis et al. (2002) measured FeNO at 4 flow-rates (50, 100, 150, and 200 ml/s) in 20 
patients with scleroderma (SSc). The SSc group (n=20) was divided into: 1) SSc-ILD without 
pulmonary hypertension (n=15), and 2) SSc with pulmonary hypertension (n=5). Patients with 
primary pulmonary hypertension (n=5) and healthy controls (n=20) were also included. Ten 
patients in SSc were on treatment with immunosuppressive agents at enrollment. Overall, in 
patients with SSc, CAlvNO was significantly higher than controls (4.7 ± 0.5 ppb, 4.1 ± 0.3 ppb, 
respectively; p< 0.001), whereas JAWNO was lower (0.6 ± 0.1 nl/sec, 1.2 ± 0.2 nl/sec, 
respectively; p= 0.01). Except for a significantly higher CAlvNO in SSc-PH group, there was no 
significant difference in FeNO levels and JAWNO. Again, due to the small and unequal sample 
size among groups and potential effect from medications, it is difficulty to attribute the cause of 
these findings. As with the study by Lehtimaki et al (2001), there was a significant negative 
correlation between CAlvNO and DLCO (r= -.66, p=.002).                
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2.4 SIGNIFICANCE & INNOVATION 
Compared with single breath exhaled NO measurement (FeNO), multiple flow-rate NO 
measurement offers the potential to differentiate exhaled NO from the alveolar and airway 
compartments. Because the contributions of the two compartments can be evaluated separately, 
this technique may provide more specific information about the site of inflammation. e. g, 
airways or alveoli (American Thoracic Society, 2005). In sarcoidosis and IPF, inflammation may 
occur in the early stages of the disease. If exhaled NO could be shown to reflect changes in 
disease activity or response to therapy, it would provide an easily reproducible means of 
monitoring change over time.  In particular, the multiple breath flow measurements may have 
utility in this regard. More information regarding the inflammatory and fibrosing changes which 
are typical in patients with these types of ILD may help to increase understanding of the disease 
progression and the impact of these changes on patient symptoms.  Therefore, we choose to 
conduct a pilot study in an attempt to further clarify the relationships between exhaled NO 
(FeNO, CAlvNO, JAWNO) and clinical information (dyspnea, pulmonary function tests, disease 
activity) in patients with sarcoidosis and IPF.    
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3.0  METHODS 
3.1 DESIGN 
A comparative descriptive correlational design was used. Three groups of subjects were enrolled: 
1) patients with IPF (IPF); 2) patients with sarcoidosis (sarcoidosis), and 3) healthy non-
smokers (control). For all groups, FeNO was measured at seven separate flow rates (50, 100, 
150, 200, 250, 300, and 400 ml/sec), applied in random order. To provide information about 
dyspnea, patients with sarcoidosis were asked to complete the UCSD Shortness of Breath 
Questionnaire (SOBQ) (See Appendix A). Clinical data were obtained by reviewing the medical 
record, e.g., diagnosis, years of diagnosis, past smoking history, past medical history, allergy, 
current medications, and pulmonary function tests (FEV1%, FVC%, FEV1/FVC ratio, DLCO). 
3.2 SITE AND SAMPLE 
Subjects with IPF (n=15) and sarcoidosis (n=43) were recruited from the Dorothy P. & Richard 
P. Simmons Center for Interstitial Lung Disease located in the Comprehensive Lung Center, 
University of Pittsburgh Medical Center.  Control subjects (n=20) were recruited by word-of-
mouth and from flyers giving a contact number for study information. Prospective control 
subjects were assessed for study eligibility using a screening questionnaire over the phone or 
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face-to-face interview.  In all groups, informed consent was obtained from each participant prior 
to data collection. The study protocol was reviewed and approved by the institutional review 
board (IRB) in University of Pittsburgh.  
3.2.1 IPF and Sarcoidosis  
For all patients, the entry criteria were: 1) ≥ 18 years of age, and 2) diagnosed with IPF or 
sarcoidosis. IPF was diagnosed as present when a patient met the following criteria: 1) 
abnormal HRCT that demonstrated classical features of usual interstitial pneumonia (UIP); 2) 
surgical lung biopsy for patients without a classical pattern of UIP or < 50 years of age; 3) 
exclusion of other conditions which might cause similar symptoms (Demedts & Costabel, 2002). 
For patients > 50 years of age, surgical lung biopsy was not recommended if HRCT 
demonstrated classical features of UIP.  
Sarcoidosis was confirmed by histological evidence of noncaseating epithelioid cell 
granulomas due to an unknown cause or not the result of local sarcoid reactions (Nunes, Brillet, 
Valeyre, Brauner, & Wells, 2007).  Active pulmonary sarcoidosis (Active sarcoidosis) was 
diagnosed as present when the patient met 3 or more of following criteria over 6-12 weeks: 1) 
complaints of progressive respiratory symptoms, such as shortness of breath, cough, dyspnea on 
exertion; 2) exercise desaturation of 10% or greater in arterial oxygen saturation by pulse 
oximetry (SpO2) or the need to increase the flow rate of supplemental oxygen during exertion; 3) 
pulmonary function test results (FVC, DLCO) that indicated a deterioration of 10% or greater, or 
4) evidence of worsening radiographical changes (American Thoracic Society, 1999b).  
Inactive sarcoidosis was defined as present when a patient with the diagnosis of 
sarcoidosos did not meet these criteria. For the cases of newly diagnosed sarcoidosis, disease 
activity was determined at the next follow-up visit which typically occurred 6-12 weeks after the 
initial visit.  Sarcoidosis patients were not enrolled if they had been on oral prednisone or 
methotrexate prior to clinic evaluation.   
3.2.2 Controls  
Control subjects (n=20) were required to meet the following entry criteria: 1) ≥ 18 years of 
age; 2) non-smoker or stopped smoking more than 6 months ago. Exclusion criteria were: 1) 
prior history of heart, lung, liver, kidney, endocrine, or neurological disorders, e.g., heart attack, 
COPD, cirrhosis, hepatitis, renal failure, diabetes, thyroid disease, stroke or seizure disorders 
(self-report); 2) symptoms of a respiratory tract infection < 1 month prior to the study; 3) use of 
medications 7 days prior to data collection (self-report).  
3.3 MEASUREMENT 
3.3.1 Demographic & clinical data  
Demographic and clinical data were obtained from the interview and medical record. 
Demographic data included: age, gender, and ethnicity. Clinical data included: diagnosis, years 
of diagnosis, past smoking history, current use of inhaled corticosteroids, and pulmonary 
function tests (FEV1%, FVC%, DLCO).  
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3.3.2 UCSD Shortness of Breath Questionnaire (SOBQ) 
The SOBQ was completed by asking subjects to rate the severity of shortness of breath on a 6-
point scale (0=not at all to 5=maximal or unable to do because of breathlessness) while 
performing 21 activities of daily living (ADLs) associated with varying levels of exertion (Eakin, 
Resnikoff, Prewitt, Ries, & Kaplan, 1998). There are 3 additional questions that ask daily life 
limitations due to shortness of breath, fear of over exertion and fear of shortness of breath.  If 
subjects do not routinely perform the activity, they are asked to estimate the shortness of breath 
anticipated.  The score is obtained by summing responses on the 24 items to form a total score 
(range 0-120) (Eakin et al., 1998).  In psychometric testing, internal consistency was α = 0.96 
(Eakin et al., 1998). Item-total corrections ranged from 0.49 to 0.87 (Eakin et al., 1998). SOBQ 
scores were negatively correlated with physiologic measures of disease severity (FEV1, DLCO), 
health related quality of life (Quality of Well-Being) and exercise tolerance (6 minutes walk test) 
(r= –0.41 to -0.68) and positively correlated with ratings of perceived breathlessness (Borg 
Scale) and depression (Center for Epidemiological Studies-Depression Questionnaire) (r= 0.37 to 
0.45) (Eakin et al., 1998). It takes approximately 5 minutes to complete the SOBQ (See 
Appendix A).    
3.3.3 Exhaled NO consists of FeNO, CAlvNO, and JAWNO 
3.3.3.1 FeNO 
FeNO was measured using a chemiluminescence analyzer (model LR1800; Logan Research, 
Rochester, UK) which has sensitivity to NO from 1 to 5000 parts per billion (ppb) by volume 
and a resolution of 0.3 ppb adapted for on-line recording of exhaled NO concentration. The 
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measurement technique was consistent with guidelines in the product manual and standards 
published by the American Thoracic Society/European Respiratory Society in 2005 (American 
Thoracic Society, 2005). Subjects were sitting in a chair during the entire measurement. When 
the machine gave a signal to exhale with a green light, subjects were asked to take a full 
inspiration from room air and then exhale into the machine with putting their lips around the 
mouthpiece, which was connected to the analyzer. Subjects were asked to make a full exhalation 
as long as possible without an episode of inspiration.  
Prior to each measurement, a constant flow rate was programmed in the machine prior to 
provide a different level of resistance when subjects exhale and help them to keep the constant 
flow rates. To ascertain if subjects maintained a constant flow-rate during exhalation, two 
procedures were used: 1) continuous monitoring of expiratory flow-rate graphically displayed on 
the monitor screen, and 2) feedback noise (clicking sound) from the machine in the event that the 
exhalation flow-rate exceeded the programmed limit.  If this occurred, the subject was asked to 
slow their exhalation and not fight the resistance. When a subject exhaled slower than a 
programmed constant flow rates, as indicated by the graphical change on the screen, faster 
exhalation was encouraged.      
3.3.3.2 CAlvNO, and JAWNO 
These variables were estimated using the model developed by Tsoukias and George (1998). For 
each subject, FeNO values were obtained at a total of 7 flow rates (50, 100, 150, 200, 250, 300, 
400 mL/s). A random order generator was used in order to apply random ordering for the 7 
separate flow-rates (Oxford Brooks University). Between each measurement, subjects rested for 
5 minutes. The steps of calculation of CAlvNO, and JAWNO were made using the formula by 
Tsoukias and George (1998).  
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3.4 DATA COLLECTION PROCEDURES 
3.4.1 IPF and sarcoidosis 
Data collection occurred during subjects’ clinic visit. After informed consent, demographic data 
and SOBQ (sarcoidosis only) were obtained. FeNO was measured at 7 separate flow-rates. 
CAlvNO, and JAWNO were calculated using measured FeNO values. Clinical data were obtained 
from electronic medical records.  For patients newly diagnosed with sarcoidosis, data collection 
occurred twice within a 6-12 week interval (time 1 and time 2) if possible depending on 
scheduled appointments.  Depending on disease activity, each subject was allocated to either 
Active sarcoidosis or Inactive sarcoidosis.  
3.4.2 Controls 
Data collection occurred once. After informed consent, demographic data and anthropometric 
data (height and weight) were obtained. Then FeNO was measured at 7 separate flow-rates. 
CAlvNO, and JAWNO were estimated using measured FeNO values. 
3.5 STATISTICAL ANALYSIS 
Data were analyzed using the SPSS software version 15.0 (SPSS, Inc.; Chicago, IL, USA) and 
the SAS system version 9.1 (SAS Institute; Cary, NC, USA). A preliminary analysis, conducted 
to determine if the distribution met the statistical assumptions (normality, linearity, and 
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homoscedasticity), indicated major violations in normality assumptions. Therefore, non-
parametric statistics were utilized. For clinical parameters, missing data occurred for pulmonary 
function tests in 4 subjects (3 in sarcoidosis, and 1 in IPF), length of diagnosis in 5 subjects (4 in 
sarcoidosis, and 1 in IPF), and UCSD-SOBQ in 11 sarcoidosis subjects. Given the small sample 
size, no imputation technique was attempted.  
Descriptive statistics (mean, median, standard deviation, percentage, and 95% confidence 
intervals of the mean) were used to describe all demographic and clinical variables. Exhaled NO 
(FeNO, CAlvNO, JAWNO) was measured at baseline in all groups (IPF, sarcoidosis, controls). For 
those newly diagnosed or active sarcoidosis patients who were not yet on treatment, data 
collection occurred at least twice (time 1 and time 2). In all cases, p-value less than 0.05 was 
considered statistically significant. The statistical analysis for each Specific Aim was as follows: 
Specific Aim 1. To compare FeNO levels measured at 7 flow rates (50, 100, 150, 200, 
250, 300, and 400 ml/s) between patients with IPF or sarcoidosis and healthy non-smoking 
subjects (controls) 
Due to the violation of normality distribution that could not be solved by transformation, 
Mann-Whitney U test was used.  
Specific Aim 2. To compare calculated airway wall NO flux (JAWNO) and alveolar NO 
concentrations (CAlvNO) between patients with IPF or sarcoidosis and healthy non-smoking 
subjects (controls) 
Due to the violation of normality distribution that could not be solved by transformation, 
Mann-Whitney U test was used.  
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Specific Aim 3. To examine the relationship between exhaled NO (FeNO, CAlvNO, 
JAWNO) and selected clinical variables (dyspnea, pulmonary function tests) in patients with IPF 
or  sarcoidosis 
Spearman’s rank correlation was used. 
Exploratory Aim 1. To compare exhaled NO (FeNO, CAlvNO, JAWNO) between patients with 
active sarcoidosis and patients with inactive sarcoidosis  
Mann-Whitney-U test (non-parametric) was used. 
Exploratory Aim 2. To examine changes in exhaled NO (FeNO, CAlvNO, JAWNO) over time 
(from initial clinic visit to follow-up visit) in patients with active sarcoidosis completed follow-
up.  
Wilcoxon signed rank test was used. 
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4.0  RESULTS 
4.1 SAMPLE DESCRIPTION 
The study sample consisted of a total of 78 participants (sarcoidosis, n=43; IPF, n=15, controls 
n=20) recruited from May 2006 to November 2007 (Table 4).  
 Patients with IPF were significantly older than patients with sarcoidosis and controls, F 
(2, 75) =16.94, p <0.001. Whereas patients with IPF were all White Caucasian, approximately 
40% of patients with sarcoidosis were African American. Length of diagnosis were significantly 
longer in patients with sarcoidosis than that of patents with IPF, t (45.61) =2.80, p=0.007. In 
patients with sarcoidosis, a majority of patients were on ICS. 
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 Table 4. Subject Characteristics at enrollment 
 
*Note: Data are missing for: PFTs 4 subjects (Sarcoidosis=3; IPF=1); Length of Diagnosis 5 subjects 
(Sarcoidosis=4; IPF=1); SOBQ 11 subjects (Sarcoidosis=11) 
Definition of abbreviations: ICS, inhaled corticosteroids; PFTs, pulmonary function tests; UCSD-SOBQ, 
University of SanDiego Shortness of Breath Questionnaire.  
^UCSD-SOBQ total scores range from 0 to 120 (higher score= worse shortness of breath).  
4.2 EXHALED NO IN IPF 
4.2.1 FeNO, CAlvNO and JAWNO 
In patients with IPF, FeNO was not significantly different from that of controls for the 7 flow 
rates (Table 5). CAlvNO was significantly higher in patients with IPF compared to controls, 
Mann-Whitney U = 86.0, p= 0.03. There was no significant difference in JAWNO between 
patients with IPF and controls, Mann-Whitney U = 104.0, p= 0.13.  
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Table 5. Comparison of FeNO at 7 flow rates, JAWNO, and CAlvNO: IPF and Controls 
 
Note: Mann-Whitney U test, *p<0.05  
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4.2.2 Correlation with clinical data 
Correlations between pulmonary function data and exhaled NO (FeNO, CAlvNO, or JAWNO ) in 
patients with IPF are summarized in Table 6. In patients with IPF, there were significant negative 
correlations between CAlvNO and FEV1% (r=-0.58, p=0.03) and FVC% (r=-0.67, p=0.01), but 
not DLCO% (r=-0.21, p=NS). With this exception, no significant correlations were seen.   
 
Table 6. Correlation between exhaled NO (FeNO at 50ml/sec, CAlvNO, or JAWNO) and pulmonary 
function tests in IPF (n=15) 
 
Note; Spearman’s rank correlation, * p <0.05 
4.3 EXHALED NO IN SARCOIDOSIS 
4.3.1 FeNO, CAlvNO and JAWNO 
The first research questions posed by this study involved a comparison of FeNO, CAlvNO and 
JAWNO measured at 7 flow rates (50, 100, 150, 200, 250, 300, and 400 ml/s).  FeNO levels 
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showed a similar pattern for each of the three groups, i.e., the highest level at the lowest flow rate 
(50 ml/sec) and lowest level at the highest flow rate (400 ml/sec). For FeNO, no significant 
differences were found between groups with the exception of a marginally significant difference 
(p=.05) at 50 ml/sec, with patients with sarcoidosis having a lower mean FeNO compared to 
controls (Table 7).  In addition, patients with sarcoidosis demonstrated a significantly lower 
JAWNO compared to controls, Mann-Whitney U = 293.0, p=0.04. There was no significant 
difference in CAlvNO between patients with sarcoidosis and controls, Mann-Whitney U = 384.5, 
p=.50.  
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 Table 7. Comparison of FeNO at 7 flow rates, JAWNO, and CAlvNO: Sarcoidosis and Controls 
 
Note: Mann-Whitney U test, *p<0.05  
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4.3.2 Correlation with clinical data 
Dyspnea measured by the UCSD-SOBQ was available in 32 patients diagnosed with sarcoidosis. 
There was no significant correlation between UCSD-SOBQ scores and FeNO at 50ml/sec, 
CAlvNO, or JAWNO (r= -0.29, p= 0.11; r= 0.16, p=0.39, and r=-0.25, p=0.17, respectively). 
Pulmonary function data were available 40 patients diagnosed with sarcoidosis. Correlations 
between pulmonary function data and exhaled NO (FeNO at 50ml/sec, CAlvNO, or  JAWNO ) are 
summarized in Table 8. In patients with sarcoidosis, there were significant negative correlations 
between CAlvNO and FVC% (r=-0.51, p=0.001) and DLCO% (r=-0.41, p=0.008).  With this 
exception, no significant correlations were seen.  
 
Table 8. Correlation between exhaled NO (FeNO at 50ml/sec, CAlvNO, or JAWNO) and pulmonary 
function tests in sarcoidosis (n=40) 
 
Note; Spearman’s rank correlation, * p <0.05 
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4.4 EXPLORATORY AIMS 
4.4.1 Exhaled NO (FeNO, CAlvNO, JAWNO) depending on disease activity 
Of 43 patients with sarcoidosis, 8 were diagnosed with active sarcoidosis. In all subjects, 
multiple flow-rates exhaled NO measurement was obtained prior to treatment. Table 9 
summarizes characteristics of patients with active (n=8) and inactive (n=35) disease. 
 
Table 9. Baseline Demographic and Clinical Characteristics: Active & Inactive sarcoidosis 
 
Note: χ2-test was used for gender, race, smoking history, and ICS use. Independent sample t-test was used 
for age, and PFTs. Mann Whitney U test was used for length of diagnosis and UCSD- SOBQ. UCSD-
SOBQ total scores range from 0 to 120 (higher score= worse shortness of breath). 
Definition of abbreviations: ICS, inhaled corticosteroids; PFTs, pulmonary function tests; UCSD-SOBQ, 
University of SanDiego Shortness of Breath Questionnaire. 
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Patients with active and inactive sarcoidosis did not differ significantly in regard to 
baseline demographics and clinical characteristics.  No significant differences was found in 
FeNO or JAWNO depending on disease activity, except significantly lower CAlvNO in patients 
with active sarcoidosis (Mann-Whitney U=73.0, p=0.04) (Table 10). 
 
Table 10. Comparison of FeNO at 7 flow rates, JAWNO, and CAlvNO at baseline: Active & Inactive 
sarcoidosis 
 
Note: Mann-Whitney U test, * p<0.05 
4.4.2 Difference in exhaled NO (FeNO, CAlvNO, JAWNO) over time 
In 6 patients with active sarcoidosis, exhaled NO (FeNO, CAlvNO, JAWNO) was measured before 
and after initiating treatment (Table 11). With one exception, all were on ICS at enrollment. 
Follow-up measurements were obtained at intervals ranging from 3 to 23 weeks. During this 
time interval, each subject was treated with prednisone and methotrexate using various doses. 
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Table 11. Characteristics of subjects with Active sarcoidosis (n=6) 
 
Note: UCSD-SOBQ total scores range from 0 to 120 (higher score= worse shortness of breath).  
Definition of abbreviations: ICS, inhaled corticosteroids; PFTs, pulmonary function tests; UCSD-SOBQ, 
University of SanDiego Shortness of Breath Questionnaire. 
 
When exhaled NO (FeNO, CAlvNO, JAWNO) was compared between before (Time 1) and 
after treatment (Time 2), there was no significant change in FeNO, CAlvNO, and JAWNO 
(Wilcoxon Signed Rank Test, Z = -.676, p=NS, Z = - 1.342, p=NS, Z = -.314, p=NS, 
respectively). 
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5.0  DISCUSSION 
The major findings in patients with IPF were: 1) FeNO was not significantly different from that 
of controls for the 7 flow rates; 2) while there was no significant difference in JAWNO compared 
with controls, CAlvNO was significantly higher, and 3) CAlvNO showed significant negative 
correlations with FEV1% and FVC%.  In patients with sarcoidosis, major findings were: 1) 
FeNO at a flow rate of 50 ml/sec was lower than that of controls but the level of significance was 
marginal (p=.05); 2) in addition, JAWNO was significantly lower in patients with sarcoidosis 
compared to controls, a similar directional change; however CAlvNO did not differ significantly 
from controls; 3) CAlvNO showed significant negative correlations with FVC% and DLCO%.   
 In addition, the subset of patients with active sarcoidosis (n=8) had significantly lower 
CAlvNO compared with those with inactive sarcoidosis (n=35), but no significant difference in 
FeNO and JAWNO. In patients with active sarcoidosis who completed follow-up at various 
intervals (n=6), exhaled NO (FeNO, CAlvNO and JAWNO) did not change significantly as a result 
of treatment. 
5.1 IPF 
In the present study, FeNO in IPF was not significantly different from controls for all 7 flow 
rates. Contradictory findings were reported from the one study that exclusively recruited patients 
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with IPF (Paredi et al., 1999). In 11 patients with IPF, Paredi et al. (1999) found that FeNO was 
significantly higher than that of healthy non-smokers. They also reported that, although FeNO in 
patients on oral steroids was significantly lower compared to those not on steroids, FeNO levels 
in steroid users were still higher than healthy non-smokers (Paredi et al., 1999).  When patients 
enrolled in our study were compared with those enrolled by Paredi et al (1999), there appeared to 
be a difference in time since the diagnosis of IPF based on the extent of decrement in pulmonary 
function tests. In the present study, the mean length of time since diagnosis in IPF subjects was 
38 months. Although the duration of time since patients were diagnosed with IPF was not 
mentioned by Paredi et al. (1999), a comparison of the mean FVC (73%) and DLCO levels (61%) 
of subjects enrolled in their study with those in the present study  (68.4%, 46.8%, respectively), 
suggests that patients in the present study had more advanced disease.  Based on findings from 
the study by Saleh, et al. (1997), that evaluated inflammation in tissue samples, differences in 
disease progression in IPF might cause differences in production of FeNO (Saleh, Ernst, Lim, 
Barnes, & Giaid, 1998). In early stages of IPF, there was increased activation of lung 
inflammatory cells which stimulated the production of iNOS and ultimately increased the 
production of NO. Whereas iNOS activity is increased in inflammatory cells, little or no iNOS 
activity was reported in fibrotic lesions (Saleh, Barnes, & Giaid, 1997). Based on these reports, it 
can be speculated that FeNO might be increased in early inflammatory stage of IPF. However 
once fibrosis becomes more predominant, FeNO can be lower than normal. In future studies, it 
would be important to consider disease stage when comparing findings in patients with IPF. 
In patients with IPF, whereas JAWNO did not show any significant difference compared 
with that of healthy controls, CAlvNO was significantly higher. Our finding suggests there may be 
inflammations at the alveolar level in patients with IPF. Our finding is consistent with the finding 
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from the study by Brindicci et al. (2005) that reported significantly higher CAlvNO in IPF 
compared to healthy non-smoking controls. In our study, a significant negative correlation was 
found between CAlvNO and FVC% and FEV1%. This finding supports the potential of 
inflammatory changes at the alveolar level in patients with IPF that is associated with worsening 
of restrictive and obstructive changes in their lungs.  
5.2 SARCOIDOSIS 
In the present study, FeNO at a flow rate of 50 ml/sec was lower than that of controls with a 
marginal statistical significance. For the remaining flow rates (from 100 ml/sec to 400 ml/sec), 
there was no significant difference between patients with sarcoidosis and controls. This finding is 
contradictory to prior studies which reported either no difference (O'Donnell et al., 1997; Ziora et 
al., 2004; Wilsher et al., 2005) or a significantly higher FeNO (Moodley et al., 1999) in patients 
with sarcoidosis compared with healthy non-smoking controls. There are several possible 
reasons for these contradictory findings.  First, approximately 70% of patients with sarcoidosis 
recruited for this study were prescribed ICS, whereas none of the patients in prior studies were 
on oral or inhaled corticosteroids (Moodley et al., 1999; O'Donnell et al., 1997; Ziora et al., 
2004; Wilsher et al., 2005).  The potential of ICS to reduce airway inflammation and, hence, 
exhaled NO levels is well established (S. Kharitonov et al., 2000; S. Kharitonov et al., 1996). 
However, it is unclear whether use of ICS could cause FeNO levels to decrease to a level lower 
than that of healthy non-smokers. No literature was identified that examined the change in FeNO 
in response to the use of ICS in patients with sarcoidosis.  
 54 
In the study by Moodley et al. (1999), the effect of 6 weeks of oral steroids (30mg/day) 
was measured in a subgroup of patients with active sarcoidosis (n=8). In this study, FeNO was 
significantly decreased after the treatment (from 9.7 ± 0.5 ppb to 5.9 ± 0.7 ppb, p<0.05), but 
FeNO values remained higher than those of healthy controls (4.1 ± 0.2 ppb). Yates et al. (1995) 
reported no change in FeNO in response to oral steroids (30mg/day for 3 days) in healthy 
children (n=6) whereas FeNO was significantly decreased after asthmatic children were treated 
with the same regimen (n=7) (D. H. Yates, Kharitonov, Robbins, Thomas, & Barnes, 1995). 
Based upon the findings from Yates et al. (1995), it appears that FeNO in healthy individuals is 
not affected by the use of steroids. Given this evidence, it is difficult to explain the mechanisms 
responsible for the lower FeNO seen in patients with sarcoidosis. 
Compared with FeNO levels reported in 4 prior studies (range of mean 6.7- 9.8 ppb; 
Moodley et al., 1999; O'Donnell et al., 1997; Ziora et al., 2004; Wilsher et al., 2005), mean 
FeNO in our study was much higher for both patients and controls. It is possible that extraneous 
factors influenced FeNO e.g. ambient NO, room temperature, etc. To explore this possibility, the 
relationship between FeNO and ambient NO at the time of measurement was examined. No 
significant correlation was found between FeNO and ambient NO (Spearman’s rho = -0.16, 
p=0.93). Howeever, the ambient NO that each subject was exposed to prior to obtaining study 
data could also influence FeNO. Influence of this potentially confounding variable was not 
measured or controlled in this study. It is possible that control subjects had undiagnosed 
conditions that might have led to an elevated FeNO level. However, controls were carefully 
screened during recruitment.   
Prior studies have attributed changes in FeNO to changes in airway caliber. Because 
pulmonary function tests were not performed for controls, it is unknown if these parameters were 
 55 
within normal limits. Mean FEV1% in patients with sarcoidosis was below normal. Bohadana et 
al. (2008) reported a significant prediction of FeNO by FEV1%/FVC ratio in 39 healthy non-
smokers (t=7.4, p<0.001) (Bohadana, Michaely, Teculescu, & Wild, 2008). Based upon findings 
from Bohadana et al. (2008), the lower FeNO in sarcoidosis might be due to a mechanical 
change in airways. Ho et al. (2000) reported a significant positive correlation between FEV1% 
and FeNO in steroid naïve patients with asthma (n=12; r=0.9, p<0.001), but no correlation in 
healthy controls (n=17; r=-0.13, p=0.06) (Ho, Wood, Robson, Innes, & Greening, 2000). Ho et 
al. (2000) reasoned that decreased airway caliber during bronchoconstriction may increase 
airflow velocity when patients exhale with a constant flow rate, with a resultant change in FeNO. 
This could be a possible explanation for patients with sarcoidosis in our study. 
JAWNO in patients with sarcoidosis was significantly lower than that of controls. FeNO 
level measured at lower flow rates reflects more contribution from airway compartment. 
Therefore, FeNO, which is measured at a flow rate of 50 ml/sec, would also reflect contribution 
from the airway compartment. The finding of a significantly lower JAWNO in our sample is 
consistent with the finding of a significantly lower FeNO and can be attributed to the same 
rationale discussed in the prior paragraph.  
In patients with sarcoidosis, whereas FeNO and JAWNO did not show a significant 
correlation with any pulmonary function test result, CAlvNO showed significant correlations with 
FVC% and DLCO%. These findings indicate worsening of restrictive pattern and decreased 
diffusion capacity that could alter the alveolar concentration of NO. Subtle increase in CAlvNO in 
patients with sarcoidosis reflects increased alveolar inflammation. 
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5.3 EXPLORATORY AIM: INACTIVE VS. ACTIVE SARCOIDOSIS 
In 43 patients with sarcoidosis, 8 patients diagnosed with active sarcoidosis were recruited before 
being on treatment. Compared with patients with inactive sarcoidosis (n=35), CAlvNO was 
significantly lower in active sarcoidosis, whereas other values  (FeNO and JAWNO) did not show 
any significant difference. Two possible reasons can be suggested. First, unequal sample size 
between two groups (8 vs. 25) is problematic in this comparison. Second, a majority of patients 
with active sarcoidosis (7 of 8, 87.5%) were on ICS at enrollment. Therefore, the influence of 
ICS might be an explanation for the lower CAlvNO in active sarcoidosis.  
To further examine possible differences in our sample, an effort was made to compare the 
difference in CAlvNO after controlling for the effect of ICS. However, due to limitations in 
conducting the analysis (e.g., normality violation and unequal sample size), this analysis could 
only be done for patients with inactive sarcoidosis (23 on ICS, 12 not on ICS) as only 8 patients 
were enrolled with active sarcoidosis. Contradictory to our assumption, CAlvNO was significantly 
higher in patients with inactive sarcoidosis who were on ICS compared to those not on ICS 
(5.94±2.88 ppb vs. 5.38 ± 6.55 ppb, respectively; Mann-Whitney U = 71, p=0.02). Due to 
limitations in this post-hoc analysis resulting from the sample size and large standard deviation, 
it remains unclear whether the effect of ICS on CAlvNO is similar in patients with active 
sarcoidosis. The effect of ICS on CAlvNO in sarcoidosis needs further exploration. 
For patients with active sarcoidosis who completed follow-up, in all 6 cases, exhaled NO 
(FeNO, CAlvNO and JAWNO) did not change significantly as a result of treatment with 
prednisone and methotrexate. Our finding is not consistent with the report by Moodley et al. 
(1999) that showed a significant decrease in FeNO after 6 weeks of treatment with oral 
prednisone (40 mg) in 8 newly diagnosed patients with sarcoidosis. Potential effects of ICS, 
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heterogenous patient characteristics, various treatment regimens and follow-up intervals might 
be possible explanations for such inconsistency between two studies.  
Although our sample was composed of patients who met ATS criteria for the diagnosis of 
sarcoidosis, our findings must be interpreted cautiously for several reasons including an unequal 
sample size (8 active vs. 35 inactive), the variety in follow-up intervals and large individual 
variance in exhaled NO (FeNO, CAlvNO, JAWNO). Heterogeneous demographic and clinical 
characteristics in patients with active sarcoidosis may also contribute to our findings.   
5.4 LIMITATIONS 
This study had a number of limitations. First, the sample size was small despite a relatively long 
recruitment interval (18 months) in an ILD specialty clinic. Second, exhaled NO levels are 
known to vary due to multiple reasons, e.g. individual difference, different analyzer, etc 
(American Thoracic Society, 2005; Borrill et al., 2006). In our study, large individual variances 
in exhaled NO were consistent across three subject groups. Although attempts have been made to 
standardize measurement, there are still many factors that potentially influence exhaled NO 
measurement that have not been clarified. The goal of recruiting a larger sample would require a 
multi-center study. Despite the benefit in terms of available subjects, using multiple sites would 
introduce new challenges. Exhaled NO measurement could vary depending on equipment made 
by different manufacturers, slightly different calibration and measurement ranges. Therefore, for 
feasibility and consistency of measurement, obtaining exhaled NO measurement with the same 
equipment in the same laboratory environment is the safest choice. In the present study, all 
measurements were obtained in the same laboratory using a single analyzer. To maintain 
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consistency, all measures of exhaled NO were obtained in the same space during the daytime 
(between 9am to 5pm). In spite of this effort, there was variability in room temperature and 
distribution of ambient air due to failure of the air conditioning system in the examination area 
for 3 weeks of data collection.   
In this study, we did not exclude subjects who were on ICS. Exhaled NO levels decrease 
in response to the use of inhaled corticosteroids (S. A. Kharitonov, Yates, Chung, & Barnes, 
1996; Smith et al., 2005).  Almost 70% of patients with sarcoidosis and 20% with IPF were on 
ICS at enrollment, which makes it difficult to compare findings of the present study with 
previous studies. In prior studies, none of the subjects were on inhaled or oral corticosteroids at 
enrollment (Moodley et al., 1999; O'Donnell et al., 1997; Ziora et al., 2004; Wilsher et al., 2005). 
We did not apply the use of ICS as exclusion criteria because it would have limited enrollment as 
inactive patients managed in our clinic are commonly prescribed ICS for symptom management 
of reactive airways disease. It would be preferable to exclude patients on ICS to improve 
understanding on mechanisms of exhaled NO production in these population. However, 
clinically, airway hyperrreactivity is common in many patients with sarcoidosis (Aggarwal, 
Gupta, Chandrasekhar, & Jindal, 2004; Manresa Presas, Romero Colomer, & Rodriguez 
Sanchon, 1986; Marcias, Ledda, Perra, Severino, & Rosetti, 1994; Shorr, Torrington, & Hnatiuk, 
2001) and ICS are commonly prescribed to manage this problem. Therefore, accomplishing this 
goal would be difficult.   
In healthy non-smokers, subject screening was conducted based upon self-reported health 
information. Therefore, there is always possibility to miss important information which 
potentially influence exhaled NO levels, e.g. smoking, alcohol use, and unknown allergy. No 
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pulmonary function tests data was obtained in healthy non-smokers, which might be helpful to 
understand the relationship between exhaled NO levels and pulmonary function tests results.  
For exploratory aims, a limited numbers of subjects were available. Because many 
individuals with active sarcoidosis were already on treatment, it was difficult to recruit subjects 
with active sarcoidosis prior to initiating treatment regimen. Obtaining timely follow-up data was 
a challenge due to frequent cancellation of regular follow-up visit by patients. Given the small 
sample and variable follow-up intervals, it is premature to hypothesize the direction of change in 
exhaled NO in sarcoidosis depending on disease activity or response to treatment regimen.  
5.5 IMPLICATIONS FOR FUTURE RESEARCH 
Findings from the present study are premature to determine the usefulness of exhaled NO 
monitoring in patients with sarcoidosis or IPF. Evaluation of the usefulness of exhaled NO in IPF 
and sarcoidosis would require a substantially larger sample in order to examine subgroup 
differences. In these disease conditions, the pattern of monitoring disease progression relies 
heavily rely on patients’ individual symptoms, pulmonary function tests, and radiographic 
images. Therefore, in order to obtain measurements at uniform intervals it would be necessary to 
provide incentives for study participation. Additional well-controlled studies are needed to 
determine the benefits of this monitoring technique in this group of patients.  
This study used 7 flow rates that ranged between 50 ml/sec and 400 ml/sec to estimate 
CAlvNO and JAWNO. The range of flow rates is set differently for different analyzers and there is 
no standard regarding the number of breaths and range of the flow rates.  Multiple flow rates NO 
measurement involves more time than a single breath measurement. Some low or high flow 
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rates, e.g. 50 ml/sec or 400 ml/sec, required more effort from patients to maintain a constant flow 
rate. If similar CAlvNO and JAWNO values can be estimated with using fewer breaths and less 
challenging flow rates, it will decrease time spent in measurement and subject burden. 
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